What the studies show
A few small trials and open-label series report modest changes; no adequately powered randomised trial in healthy adults.
A few small or poorly-controlled human studies. Enough to be interesting; not enough to count on. Most of what gets called “clinically proven” online lives here.
- 1Sermorelin evidence review: Geref approval history, withdrawal, and adult off-label data.Evidence review, 2026Secondary source used for approval and withdrawal history; adult RCT data described as limited.
In context
Sermorelin is the first 29 amino acids of growth-hormone-releasing hormone — the active fragment. It was FDA-approved in 1990 as Geref for diagnosing growth-hormone deficiency in children, and the brand was withdrawn in 2008 for commercial reasons, not safety. It reliably raises growth hormone and IGF-1. The adult anti-ageing and body-composition claims rest on small open-label studies, not randomised trials.
Sermorelin is withdrawn (us brand). Legal status differs by country — see the regulation section or the jurisdiction pages.
Questions
Is Sermorelin proven to help with body composition in adults?
What studies are behind the grade?
Is Sermorelin approved for this?
Other outcomes for Sermorelin
- AGrowth hormone / IGF-1 elevationApproval-grade paediatric data
- DSleep qualityAnecdotal / small
- CSafety in adultsadverseCompounding-era use
Reviewed 2 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →